Hansa Biopharma reports widened operating loss for Q2 2026

Hansa Biopharma reported an operating loss of 174 million SEK for Q2 2026, an increase from the 155 million SEK loss recorded in the same period last year. The widening deficit reflects ongoing operational costs in the biotech sector, though the report lacks specific details on R&D milestones or liquidity runway.